key: cord-0795112-2aslzgdk
authors: Rajah, Maaran Michael; Hubert, Mathieu; Bishop, Elodie; Saunders, Nell; Robinot, Remy; Grzelak, Ludivine; Planas, Delphine; Dufloo, Jérémy; Gellenoncourt, Stacy; Bongers, Alice; Zivaljic, Marija; Planchais, Cyril; Guivel-Benhassine, Florence; Porrot, Françoise; Mouquet, Hugo; Chakrabarti, Lisa; Buchrieser, Julian; Schwartz, Olivier
title: SARS-CoV-2 Alpha, Beta and Delta variants display enhanced Spike-mediated Syncytia Formation
date: 2021-08-02
journal: bioRxiv
DOI: 10.1101/2021.06.11.448011
sha: a310d6f6f172960e115841352ae0204a9664d8b3
doc_id: 795112
cord_uid: 2aslzgdk

Severe COVID-19 is characterized by lung abnormalities, including the presence of syncytial pneumocytes. Syncytia form when SARS-CoV-2 spike protein expressed on the surface of infected cells interacts with the ACE2 receptor on neighbouring cells. The syncytia forming potential of spike variant proteins remain poorly characterized. Here, we first assessed Alpha and Beta spread and fusion in cell cultures. Alpha and Beta replicated similarly to D614G reference strain in Vero, Caco-2, Calu-3 and primary airway cells. However, Alpha and Beta formed larger and more numerous syncytia. Alpha, Beta and D614G fusion was similarly inhibited by interferon induced transmembrane proteins (IFITMs). Individual mutations present in Alpha and Beta spikes differentially modified fusogenicity, binding to ACE2 and recognition by monoclonal antibodies. We further show that Delta spike also triggers faster fusion relative to D614G. Thus, SARS-CoV-2 emerging variants display enhanced syncytia formation. Synopsis The Spike protein of the novel SARS-CoV-2 variants are comparative more fusogenic than the earlier strains. The mutations in the variant spike protein differential modulate syncytia formation, ACE2 binding, and antibody escape. The spike protein of Alpha, Beta and Delta, in the absence of other viral proteins, induce more syncytia than D614G The ACE2 affinity of the variant spike proteins correlates to their fusogenicity Variant associated mutations P681H, D1118H, and D215G augment cell-cell fusion, while antibody escape mutation E484K, K417N and Δ242-244 hamper it. Variant spike-mediated syncytia formation is effectively restricted by IFITMs

SARS-CoV-2 was initially discovered during an outbreak in Wuhan, China, before it 51 became pandemic (Huang et al, 2020a) . Since its emergence, the ancestral Wuhan strain has 52 been supplanted by variants harboring a variety of mutations. Several of these mutations occur 53 in the highly antigenic Spike (S) protein which endowed many of the variants with the ability to 54 evade part of the neutralizing antibody response (Liu et 

We next explored the impact of variant-associated mutations on S binding to the ACE2 256 receptor. To this aim, we transiently expressed each mutant protein in 293T cells. Cells were 257 then stained with a serial dilution of soluble biotinylated ACE2, revealed with fluorescent 258 streptavidin and then analyzed by flow cytometry (Fig. 5A) . Titration binding curves were 259 generated and EC50 (the amount of ACE2 needed for 50% binding) was calculated. The S 260 protein of Alpha had the highest affinity to ACE2, confirming previous results by us and others 261 substitution present in the Beta S decreased ACE2 binding ( Fig. 5B and EV7C) . The E484K 267 mutant had a slightly, but not significantly, higher binding to ACE2 (Fig. EV7C) . This was 268 corroborated by the observation that addition of the E484K mutation to Alpha S protein also 269 slightly increased ACE2 binding (Fig. 5B and EV7A) . Mutation in the S1/S2 cleavage site, 270 HR1/HR2 sites or NTD did not have any significant impact on ACE2 binding (Fig. 5B and EV7B-E) . 271

It is worth noting that the NTD ∆242-244 mutant displayed a marginally lower binding to ACE2 272 ( Fig. 5B and EV7B) . Therefore, the N501Y mutation is the most significant contributor to 273 increased ACE2 binding of the variants, though it does not affect cell-cell fusion on its own. The 274 K417N, ∆242-244, and E484K mutations restrict fusogenicity but differently effect ACE2 275 binding; with the former two decreasing affinity and the latter slightly increasing. 276 Therefore, ACE2 binding and fusogenicity are two functions of the S protein that can be 277 partially deconvoluted through individual mutations. 278 279

We had previously found that certain neutralizing antibodies differentially affect SARS-281

CoV-2 D614G, Alpha and Beta variants (Planas et al., 2021a) . For instance, neutralizing 282 monoclonal antibody 48 (mAb48) restricts D614G virus but not Alpha or Beta variants (Planas et 283 al., 2021a) . We sought to determine which mutations in variant S proteins contributed to the 284 lack of recognition by the neutralizing antibodies. To this aim, we assessed by flow cytometry 285 the binding of a panel of four human monoclonal antibodies (mAbs) to the different S mutants. 286

As a control we used mAb10, a pan-coronavirus antibody that targets an unknown but 287 conserved epitope within the S2 region (Planchais, manuscript in preparation). mAb10 equally 288 recognized all variants and associated individual mutations (Fig. 5C ). mAb48 and mAb98 target 289 the RBD and mAb71 the NTD (Planas et al., 2021b)(Planchais, manuscript in preparation). 290 mAb48 did not recognize the Beta variant, and more specifically did not bind to the K417N 291 mutant (Fig. 5C) . The mAb71 recognized neither Alpha nor Beta variants and did not bind to 292 their respective NTD ∆Y144 and ∆242-244 mutations. The K417N and ∆242-244 mutations were 293 also responsible for decreasing S-mediated fusion, suggesting a tradeoff between antibody 294 escape and fusion (Fig. 5C ). mAb98 did not recognize the Beta variant. However, none of the 295 associated mutations were specifically responsible for the lack of binding (Fig. 5C) , suggesting a 296 combined effect on the structure of the S protein that may affect antibody escape. 297

Therefore, several of the mutations found in the variants spike proteins are 298 advantageous in terms of antibody escape despite slightly reducing the ability the proteins to 299 fuse. 300

With the emergence and rapid spread of the Delta variant, we sought to characterize its 302 potential to form syncytia. We recently showed that the Delta variant induce large syncytia in S-303

Fuse cells (Planas et al., 2021b) . We thus compared the fusogenicity of the Delta S protein to 304 that of D614G and Alpha. We transiently expressed the three S proteins in Vero-GFP split cells. 305

The Delta S protein triggered more cell-cell fusion than the D614G variant but was similar to the 306 Alpha S protein (Fig 6A) . The fusion kinetic of the Delta S was also similar to Alpha but more 307 rapid than D614G (Fig 6B) . We confirmed that the variant S proteins were equally expressed on 308 the surface by transfecting them into non-fusogenic 293T cells and performing flow cytometry 309 upon staining with the pan-SARS-CoV-2 mAb129 (Fig EV4D) . We next examined the ACE2 310 binding potential of Delta S protein using our aforementioned soluble biotinylated ACE2. The 311

Delta S protein has a higher binding capacity to ACE2 than the D614G S protein, but the binding 312 was lower than the Alpha S protein (Fig 6C) . and Beta S proteins, in the absence of any other viral factors, produced significantly more 330 syncytia than D614G, which in turn, fused more than the Wuhan S. Comparative video 331 microscopy analysis revealed that Alpha S fused the most rapidly, followed by Beta, D614G, and 332 finally Wuhan. Thus, Alpha and Beta variants display enhanced S-mediated syncytia formation. 333

We further show that Alpha and Beta remain sensitive to restriction by IFN-β1. The 334 fusion mediated by their respective S proteins is inhibited by IFITMs. This extends previous 335 results by us and others demonstrating that ancestral Wuhan S is effectively inhibited by this 336 family of restriction factors (Buchrieser et al., 2020; . It has been recently 337 reported in a pre-print that Alpha may lead to lower levels of IFN-β1 production by infected 338

Calu-3 cells and may be less sensitive to IFN-β pre-treatment, when compared to first wave viral 339

isolates (Thorne et al., 2021) . We did not detect here differences of IFN-β1 sensitivity between 340 the variants in Vero and U2OS-ACE2 cells. Again, these discrepant results may reflect inherent 341 differences between Calu-3, Vero and U2OS-ACE2 cells, or the use of different viral isolates. 342

We then characterized the contribution of the individual mutations present in Alpha and 343

Beta S proteins to their respective fusogenicity. The highly fusogenic Alpha S consists of more 344 mutations that robustly increase fusion (P681H and D1118H) than mutations that decrease 345 fusion (∆69/70). In contrast, the Beta variant is comprised of several restrictive mutations 346 (∆242-244, K417N, and E484K) and only one mutation that modestly increased fusion (D215G). 347

The strongest increase in fusion was elicited by the P681H mutation at the S1/S2 border. This 348 mutation likely facilitates proteolytic cleavage of S and thus promotes S mediate cell-cell fusion. Alpha bound the most efficiently to ACE2, followed by Beta, D614G and finally Wuhan. 358

However, the ACE2 affinity of S proteins carrying individual mutations did not exactly correlate 359 to fusogenicity. For instance, the N501Y and D614G mutations drastically increased ACE2 360 affinity, but only D614G enhanced fusogenicity. The K417N substitution, and to a lesser degree 361 ∆242-244, had a lower affinity to ACE2 and also restricted cell-cell fusion. The E484K mutation 362 significantly restricts fusion, but mildly increases ACE2 affinity. This suggests that on the level of 363 individual S mutations, the relationship between ACE2 affinity and increased fusogenicity is not 364 always linear. Variant mutations may also confer advantages in an ACE2 independent manner. 365

Indeed, recent work has suggested that the E484 mutation may facilitate viral entry into H522 We selected a panel of 4 mAbs that displayed different profiles of binding to Alpha, 370

Beta, D614G and Wuhan S proteins. The mAb10 targeting the S2 domain recognized all variants 371

and was used as a positive control. Wuhan and D614G were recognized by the three other 372 antibodies, targeting either the NTD or RBD. Alpha lost recognition by the anti-NTD mAb71, 373

whereas Beta was neither recognized by mab71 nor by the two anti-RBD antibodies mAb48 and 374 mAb 98. Upon examining the potential of S proteins carrying individual mutations to bind to 375 human monoclonal antibodies, we found that the ones that restrict (∆242-244, K417N) or have 376 no effect on fusogenicity (∆Y144) are also not recognized by some mAbs. This suggests that 377 variant S proteins have undergone evolutionary trade off in some circumstances; selecting for 378 mutations that provide antibody escape at the detriment of fusogenicity. In accordance with 379 our findings, deep sequence binding analysis and in vitro evolution studies suggest the N501Y 380 mutation increases affinity to ACE2 without disturbing antibody neutralization (Liu et Quad dish (ibidi-#80416). Cells were allowed to settle, and fluorescence images were taken at 492 37°C every 10min up to 24h using a Nikon BioStation IMQ, with three fields for each condition. 493

Fusion defined as percent of GFP pixels was calculated with ImageJ. Pasteur. mAb10 was generated during the early stages of the epidemic from a patient infected 508 with the Wuhan strain and thus has a higher affinity for the Wuhan spike (Planas et al., 2021a) . 509

For viral replication, infected cells were fixed at each time with 4% paraformaldehyde for 30 510 mins. The cells were stained in the same manner described above with anti-spike mAb102 and 511 secondary Alexa Fluor 647 (1:500) in MACS buffer containing 0.05% saponin. The gating 512 strategy to determine spike positive cells is represented in the supplement (Fig EV1B) . 513

Cells were lysed in TXNE buffer (1% Triton X-100, 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM 515 EDTA, protease inhibitors) for 30 min on ice. Equal amounts (20-50 μg) of cell lysates were 516 analyzed by Western blot. The following antibodies were diluted in WB-buffer (PBS, 1% BSA, 517 0.05% Tween, 0.01% Na Azide): rabbit anti-human TMPRSS2 (Atlas antibodies cat# HPA035787, 518 1:1,000), rabbit anti-human actin (Sigma cat#A2066, 1:2,000), and human anti-S Serum derived 519 from a convalescent individual (1:1000). Species-specific secondary DyLight-coupled antibodies 520 were used (diluted 1:10,000 in WB-buffer) and proteins revealed using a Licor Imager. Images 521 were quantified and processed using Image Studio Lite software. experiments. Statistical analysis: One-way ANOVA compared to D614G reference, ns: non-577 significant, *P < 0. 05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Results are mean ± SD from three fields per condition from one representative experiment. right panels of A were conducted together. One-way ANOVA compared to D614G reference, ns: 607 non-significant, *P < 0. 05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns: non-significant, *P < 0. 05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 622 Results are mean ± SD from three fields per condition from one representative experiment. One-way ANOVA compared to D614G reference, ns: non-significant, *P < 0. 05, **P < 0.01, 665 ***P < 0.001, ****P < 0.0001. 666 Data are mean ± SD of at least 3 independent experiments. Statistical analysis: One-way ANOVA 697 compared to D614G reference or control plasmid transfection, ns: non-significant, *P < 0. 05, 698 **P < 0.01, ***P < 0.001, ****P < 0.0001. 699 Representative images of Vero GFP split cells 20h after transfection with each Beta variant 708 associated mutant spike. Statistical analysis: One-way ANOVA compared to D614G reference, 709 ns: non-significant, *P < 0. 05, **P < 0.01, ***P < 0.001, ****P < 0.0001. FP  HR2   TA   CTD  HR1   13  305  319  541  788  806  912  984  1163  1213  1213  1273  1237 RBD S1/S2 cleavage site S2 S1 

The new SARS-CoV-2 strain shows a stronger binding affinity to 730 ACE2 due to N501Y mutant

Systems biological assessment of immunity to mild versus severe 733 COVID-19 infection in humans

Bulkley D 735 et al (2021) Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of 736 syncytia

Effect of clinical isolate or cleavage site mutations in the SARS-CoV-739 2 spike protein on protein stability, cleavage, and cell-cell fusion

Preexisting autoantibodies to type I IFNs underlie critical COVID-19 742 pneumonia in patients with APS-1

Autoantibodies against type I IFNs in patients with life-745 threatening COVID-19

SARS-CoV-2 transmission via apical syncytia release from 748 primary bronchial epithelia and infectivity restriction in children epithelia

Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-752 induced syncytia

IFITM proteins inhibit placental syncytiotrophoblast 755 formation and promote fetal demise

Syncytia formation by SARS-CoV-2-infected cells

Three-quarters attack rate of SARS-CoV-2 in 761 the Brazilian Amazon during a largely unmitigated epidemic

Persistence of viral RNA, pneumocyte syncytia and thrombosis are 764 hallmarks of advanced COVID-19 pathology

Sequences in 766 the cytoplasmic tail of SARS-CoV-2 Spike facilitate expression at the cell surface and syncytia 767 formation

Differential cell line susceptibility to the emerging novel human betacoronavirus 2c

EMC/2012: implications for disease pathogenesis and clinical manifestation

A 773 neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-774 2

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread

Estimated transmissibility and impact of SARS-CoV-2 783 lineage B.1.1.7 in England

Drug repurposing screens reveal cell-type-specific entry pathways 786 and FDA-approved drugs active against SARS-Cov-2

Human coronavirus HKU1 infection of 788 primary human type II alveolar epithelial cells: cytopathic effects and innate immune response

Implications for the Design of Spike-Based 792

Survey of Human Chromosome 21 Gene Expression Effects on Early 795 Development in Danio rerio

SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited 798 antibodies

Genomic characteristics and clinical effect of the emergent SARS-CoV-801

UK: a whole-genome sequencing and hospital-based cohort study

Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 805 autopsy cases from Singapore

Impaired type I interferon activity and inflammatory 808 responses in severe COVID-19 patients

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing 811 antibodies

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 814 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their 817 Requirements for Receptor Expression and Proteolytic Activation

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and 820 transmission in vivo

Structural and functional properties of SARS-CoV-824 2 spike protein: potential antivirus drug development for COVID-19

SARS-CoV-2 cell-to-cell spread occurs rapidly and is insensitive to antibody 828 neutralization

Bimodular 830 effects of D614G mutation on the spike glycoprotein of SARS-CoV-2 enhance protein 831 processing, membrane fusion, and viral infectivity

Recurrent emergence and transmission of a SARS-CoV-2 spike deletion 834 H69/V70

SARS-CoV-2 structure and replication 837 characterized by in situ cryo-electron tomography

TMPRSS2 expression 839 dictates the entry route used by SARS-CoV-2 to infect host cells

Iwasa 841 H et al (2015) A new cell-based assay to evaluate myogenesis in mouse myoblast C2C12 cells

Tracking Changes in SARS-CoV-2 Spike: Evidence that 845 D614G Increases Infectivity of the COVID-19 Virus

Point mutations in the S protein connect the 847 sialic acid binding activity with the enteropathogenicity of transmissible gastroenteritis 848 coronavirus

Early transmissibility assessment of the 850 N501Y mutant strains of SARS-CoV-2 in the United Kingdom

Angiotensin-converting enzyme 2 is a functional receptor for the 854 SARS coronavirus

Syncytia formation during SARS-CoV-2 lung infection: a 856 disastrous unity to eliminate lymphocytes

The N501Y spike substitution enhances SARS-CoV-2 transmission

The N501Y spike substitution enhances SARS-CoV-2 transmission

Identification of SARS-CoV-2 spike mutations that attenuate 864 monoclonal and serum antibody neutralization

Molecular Mechanism of the N501Y Mutation for Enhanced 866 Binding between SARS-CoV-2's Spike Protein and Human ACE2 Receptor

Differential maturation and subcellular localization of severe acute respiratory syndrome 870 coronavirus surface proteins S, M and E

Molecular dynamic 872 simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of 873 E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater 874 than N501Y mutant alone, potentially resulting in an escape mutant

Hydroxychloroquine-mediated 877 inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2

Characterization and Treatment of SARS-CoV-2 in Nasal 880 and Bronchial Human Airway Epithelia

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 883 variants to neutralizing antibodies

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody 886 neutralization

Systematic analysis of SARS-CoV-2 infection of an ACE2-889 negative human airway cell

Role of the spike glycoprotein of human Middle East 891 respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation

SARS-CoV-2 B.1.1.7 and B.1.351 spike 894 variants bind human ACE2 with increased affinity

The effect of spike mutations on SARS-CoV-2 neutralization

SARS-CoV-2 infection damages airway motile cilia and impairs 900 mucociliary clearance

SARS-CoV-2 infection induces the dedifferentiation of 903 multiciliated cells and impairs mucociliary clearance

Resurgence of COVID-19 in Manaus, Brazil, 906 despite high seroprevalence

SARS-CoV-2 requires cholesterol for viral entry and pathological 909 syncytia formation

Opposing activities of IFITM proteins in SARS-CoV-2 912 infection

More than meets the I: the diverse antiviral and cellular 914 functions of interferon-induced transmembrane proteins

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Emergence and rapid spread of a new severe acute respiratory 920 syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South 921

Evolution of enhanced innate immune evasion by the 924 SARS-CoV-2 B.1.1.7 UK variant

Spike Protein Strengthens the Interaction between COVID-19 and its Receptor ACE2

Pulmonary Pathology of Early-Phase

COVID-19) Pneumonia in Two Patients With Lung Cancer

Replicative fitness SARS-CoV-2 20I/501Y.V1 variant in a human 933 reconstituted bronchial epithelium

Presence of Genetic 936 Variants Among Young Men With Severe COVID-19

Escape from neutralizing antibodies by SARS-CoV-2 939 spike protein variants

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Sahay 944 RR, Shete AM et al (2021) Neutralization of variant under investigation B.1.617 with sera of 945 BBV152 vaccinees

Structural and Functional Analysis of the D614G SARS-CoV-2 948

SARS-CoV-2 RBD <em>in vitro</em> evolution follows contagious mutation 951 spread, yet generates an able infection inhibitor

Antiviral Protection by IFITM3 In Vivo

Viral and host factors 954 related to the clinical outcome of COVID-19

SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination

Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike 960 glycoprotein

Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients

Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells